Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 64
Summary
- Conditions
- Carcinoid Tumor
- Neuroendocrine Tumors
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03420521
- Collaborators
- Bristol-Myers Squibb
- Investigators
- Principal Investigator: Christine Hann, MD/PhD Johns Hopkins University
Get Well Soon